Back
#1
23.0%
Top 0.2%
9.7%
#1
9.3%
Top 27%
6.2%
Top 2%
6.2%
Top 78%
5.8%
Top 0.3%
4.0%
Top 3%
4.0%
Top 32%
2.9%
Top 4%
2.0%
Top 11%
2.0%
#1
2.0%
Top 5%
1.6%
Top 2%
1.4%
Top 4%
1.4%
Top 14%
1.4%
Top 6%
1.2%
Top 10%
1.0%
Top 19%
1.0%
Top 7%
1.0%
Top 5%
0.7%
Top 95%
0.7%
Top 16%
0.7%
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
2022-06-16
infectious diseases
Title + abstract only
View on medRxiv
Show abstract
BackgroundIn the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. ObjectiveTo assess whether nirmatrelvir plus ritonavir reduces risk of hospitalization among outpatients with early COVID-19 in the setting of prevalent SARS-CoV-2 immunity and immune evasive SARS-CoV-2 lineages. DesignPopulation-based cohort s...
Predicted journal destinations
1
Clinical Infectious Diseases
219 training papers
2
JAMA Network Open
125 training papers
3
Open Forum Infectious Diseases
124 training papers
4
BMJ Open
553 training papers
5
Vaccine
140 training papers
6
PLOS ONE
1737 training papers
7
BMJ
49 training papers
8
The Journal of Infectious Diseases
137 training papers
9
Nature Communications
483 training papers
10
PLOS Medicine
95 training papers
11
BMC Medicine
155 training papers
12
Annals of Internal Medicine
27 training papers
13
Nature Medicine
88 training papers
14
New England Journal of Medicine
49 training papers
15
The Lancet Infectious Diseases
57 training papers
16
BMC Infectious Diseases
110 training papers
17
Journal of Infection
64 training papers
18
Vaccines
131 training papers
19
International Journal of Infectious Diseases
115 training papers
20
Clinical Microbiology and Infection
54 training papers
21
eClinicalMedicine
55 training papers
22
Scientific Reports
701 training papers
23
Emerging Infectious Diseases
84 training papers